Clinical Study of Bevacizumab Combined with FOLFIRI Regimen in Treatment of Advanced Colorectal Cancer

Objective To observe and evaluate the clinical efficacy, toxicity and safety of bevacizumab plus FOLFIRI regimen in the treatment of advanced colorectal cancer. Methods Forty-two advanced colorectal cancer cases were collected from 2009 to 2011 and confirmed by pathology were divided into 2 groups to receive bevacizumab plus FOLFIRI (the study group) and FOLFIRI only treatment (the control group). The efficacy side effects and survival time in two groups were observed and compared. Results Forty-two patients were all evaluable for efficacy and adverse reactions.The objective response rateof the study and control group was 45.4% and 20.0% respectively; the median overall survival of two groups was 15.7 and 12.0 months. The difference were all statistically significant (P＜0.05). After treatment, there were three kinds of decreased tumor markers in two groups, and significant difference of CEA level was just identified in study group (P＜0.05). The toxicity related to bevacizumab includes high blood pressure and bleeding,with the incidence of 27.3% and 22.7%, respectively，but all were grade Ⅰ or Ⅱ，they could be controlled after drug treatment,and didn't affect the continuity of the chemotherapy. Conclusion Bevacizumab combined with FOLFIRI regimen can improve efficacy in the treatment of advanced colorectal cancer patients, and the adverse effects were well tolerated.